Syros to Present PK and PD Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESMO 2017 Congress

Company to Also Detail SY-1365 Phase 1 Clinical Trial Design

CAMBRIDGE, Mass.--(BUSINESS WIRE)--, Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company will present pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase 2 clinical trial of SY-1425, its oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the European Society of Medical Oncology (ESMO) 2017 Congress taking place September 8-12 in Madrid, Spain. The Company will also present on the design of its Phase 1 clinical trial for SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, in patients with advanced solid tumors.

Details on the presentations are as follows:

Date & Time: Saturday, September 9, from 1:15 – 2:15 p.m. CEST (7:15 -8:15 a.m. EDT)
Presentation Title: Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients
Session Title: Haematological Malignancies
Presenter: Emmanuelle di Tomaso, Ph.D., Vice President, Translational Medicine, Syros
Abstract Number: 1032P
Location: IFEMA - Feria de Madrid, Poster area (Hall 8)

Date & Time: Monday, September 11, from 1:15 – 2:15 p.m. CEST (7:15 -8:15 a.m. EDT)
Presentation Title: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors
Session Title: Developmental Therapeutics
Presenter: Emmanuelle di Tomaso, Ph.D., Vice President, Translational Medicine, Syros
Abstract Number: 425TiP
Location: IFEMA - Feria de Madrid, Poster area (Hall 8)

About Syros Pharmaceuticals
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors, including transcriptionally dependent cancers such as triple negative breast, small cell lung and ovarian cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the clinical utility of Syros’ drug candidates, including SY-1425 and SY-1365, and the benefits of Syros’ gene control platform. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important
factors, including: Syros’ ability to: advance the development of its programs under the timelines it projects in current and future clinical trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; replicate scientific and non-clinical data in clinical trials; successfully develop a companion diagnostic test to identify patients with biomarkers associated with the RARA super-enhancer; obtain and maintain patent protection for its drug candidates and the freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into and maintain collaboration agreements with third parties; manage competition; manage expenses; raise the substantial additional capital needed to achieve its business objectives; attract and retain qualified personnel; and successfully execute on its business strategies; risks described under the caption “Risk Factors” in Syros’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, which is on file with the Securities and Exchange Commission; and risks described in other filings that Syros makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Syros expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.


**Media Contact:**
Syros Pharmaceuticals
Naomi Aoki, 617-283-4298
naoki@syros.com
or
**Investor Contact:**
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com

Source: Syros Pharmaceuticals